Magic mushroom compound tested for OCD in early trial

NCT ID NCT05546658

Ongoing Symptom relief Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study at Johns Hopkins University is testing whether psilocybin, the active compound in magic mushrooms, can safely help people with obsessive-compulsive disorder (OCD). Thirty-five adults with moderate to severe OCD who have already tried other treatments will receive psilocybin in a supportive setting. The main goal is to see if it reduces OCD symptoms, anxiety, and depression, and improves quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin
What this could lead to: If it works, this could point toward a new way to ease OCD symptoms for people who haven't responded to standard treatments.
What could go wrong: This is a very early, small study (35 people) testing safety and feasibility first. It may not show clear benefit, and psilocybin can cause temporary anxiety or distress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBSESSIVE-COMPULSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obsessive-compulsive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBSESSIVE-COMPULSIVE DISORDER

Contacts and locations

Locations

Johns Hopkins University School of Medicine

Baltimore, Maryland, 21224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.